Clinical Research Focus. 27th Edition
Navigating the Challenges: The Impact of US-China Tensions on Biopharmaceutical Innovation
The escalating tensions between the US and China have permeated various sectors, including the biopharmaceutical industry, significantly impacting companies with footprints in both countries. This article explores the implications of these tensions, focusing on the case of WuXi AppTec and the Biotechnology Innovation Organization’s (BIO) recent decision to sever ties.
Please follow the link to learn more.
First Oral Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
The EMA recommends market approval for Fabhalta (iptacopan), a groundbreaking oral treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH). Clinical trials demonstrate Fabhalta’s superiority over standard treatments, offering substantial hemoglobin improvement and reducing transfusion dependency.
Please follow the link to learn more.
Revolutionizing Diabetes Management: FDA Approves First Direct-to-Consumer Glucose Monitor
The FDA has given the green light to the Dexcom Stelo Glucose Biosensor System, the first of its kind continuous glucose monitor (CGM) that will be available directly to consumers. Slated for release in summer 2024, this innovative device offers adults over 18 who do not rely on insulin a novel way to monitor their blood sugar levels.
Please follow the link to learn more.
Unveiling Heterogeneous Impacts: AI Assistance in Radiology Practice
New study in Nature Medicine reveals surprising findings on AI assistance in radiology. Contrary to expectations, traditional factors like experience don’t reliably predict its impact. AI errors significantly affect treatment outcomes, highlighting the need for personalized clinician-AI collaboration.
Please follow the link to learn more.
Children achieve over a year of HIV remission following a pause in treatment.
Four children, infected with HIV before birth, have maintained undetectable levels of the virus for over a year after pausing their antiretroviral therapy (ART), showcasing promising outcomes from an NIH-funded trial. Initiated within 48 hours of birth, the ART regimen demonstrates the potential of early treatment in achieving HIV remission.
Please follow the link to learn more.
Nexalin Device Eases Symptoms of Mild Traumatic Brain Injury
Nexalin Technology’s neurostimulation device demonstrates promising results in a clinical trial for combat-related mild traumatic brain injury (mTBI) patients. Presented data shows reduced pain and post-concussive symptoms compared to sham treatment, with potential neuronal healing and improved brain function.
Please follow the link to learn more.
World Kidney Day
World Kidney Day is an annual global event on the second Thursday of March, focusing on raising awareness about kidney health and the impact of kidney diseases on individual well-being. Since its inception in 2006, it has evolved into a significant global health movement, spotlighting the substantial global health impact of kidney disease, a leading cause of global illness and death.
Please follow the link to learn more.
Exploring Clinical Trial Opportunities: Hungary’s 2024 Country Profile
Hungary is recognized for its advanced regulatory framework and state-of-the-art healthcare infrastructure, attracting pharmaceutical companies and clinical research organizations (CROs) to carry out their clinical trials there.
Please follow the link to learn more.
